Insulin lispro

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Insulin lispro
Clinical data
Trade names Humalog
AHFS/Drugs.com Monograph
MedlinePlus a697021
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Subcutaneous
Legal status
Legal status
Identifiers
CAS Number 133107-64-9 YesY
ATC code A10AB04 (WHO)
PubChem CID 16132438
DrugBank DB00046 YesY
ChemSpider none
UNII GFX7QIS1II N
KEGG D04477 YesY
Chemical data
Formula C257H389N65O77S6
Molar mass 5813.63 g/mol
 NYesY (what is this?)  (verify)

Insulin lispro (marketed by Eli Lilly and Company as Humalog) is a fast acting insulin analog. It was first approved for use in the United States in 1996, making it the first insulin analog to enter the market.[1]

Engineered through recombinant DNA technology, the penultimate lysine and proline residues on the C-terminal end of the B-chain are reversed. This modification does not alter receptor binding, but blocks the formation of insulin dimers and hexamers. This allowed larger amounts of active monomeric insulin to be immediately available for postprandial injections.[2]

Insulin lispro has one primary advantage over regular insulin for postprandial glucose control. It has a shortened delay of onset, allowing slightly more flexibility than regular insulin, which requires a longer waiting period before starting a meal after injection. Both preparations should be coupled with a longer acting insulin (e.g. Insulin degludec) for good glycemic control.

Medical uses[edit]

Insulin lispro is an FDA approved drug used to treat people living with Type 1 diabetes or Type 2 diabetes.[3] Insulin lispro has non-FDA labeled uses for diabetic nephropathy prevention, diabetic neuropathy prevention, and cardiovascular disease prevention.[3]

Side effects[edit]

Common side effects include skin irritation at the site of injection, hypoglycemia, hypokalemia, and lipodystrophy.[3] Other serious side effects include anaphylaxis, and hypersensitivity reactions.[3]

Contraindications[edit]

Do not administer insulin lispro during episodes of hypoglycemia, or if the patient has a hypersensitivity to insulin lispro or any of its excipients.[3]

Cost[edit]

In the United States as of 2015 the cost is between 10.06 and 29.36 USD per 100 units.[4]

References[edit]

  1. ^ "Drugs@FDA:FDA Approved Products: Humalog". U.S. Food and Drug Administration. Retrieved 16 November 2012. 
  2. ^ "Insulin Lispro: A Fast-Acting Insulin Analog". Retrieved 2007-06-08. 
  3. ^ a b c d e Product Information: HUMALOG(R) pen injection, insulin lispro (rDNA origin) pen injection. Eli Lilly and Company, Indianapolis, IN, 2007
  4. ^ Langreth, Robert (June 29, 2016). "Decoding Big Pharma’s Secret Drug Pricing Practices". Bloomberg. Retrieved 15 July 2016. 

External links[edit]